Nice job on the PFE/Tremelimumab quiz! When PFE out-licensed Tremelimumab to AZN in 2011 (#msg-67624944), PFE retained the right to use Tremelimumab in certain undisclosed combination regimens. On the recent Leerink webcast, PFE confirmed that use of Tremelimumab with a cancer vaccine was one of the retained uses.
How much research, if any, did you have to do to knwow the answer?
News 
Market Data 
Discover 
